Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial

Nutrition

Volumn 58, Issue , 2019, Pages 7-10

  Simental Mendía, Luis E ^a   Guerrero Romero, Fernando ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Dyslipidemia; Lipid profile; Lipids; Randomized controlled trial; Resveratrol

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RESVERATROL; SUCROSE; TRIACYLGLYCEROL; VERATROL; ANTIOXIDANT;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; LIPID BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DIETARY SUPPLEMENT; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIOXIDANTS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RESVERATROL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85054084446     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2018.06.015     Document Type: Article

References (29)

1. Nelson, RH, Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 40 (2013), 195–211.
2. Arsenault, BJ, Rana, JS, Stroes, ES, Després, JP, Shah, PK, Kastelein, JJ, et al. Beyond low-density lipoprotein cholesterol: Respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 55 (2009), 35–41.
3. Lamarche, B, Després, JP, Moorjani, S, Cantin, B, Dagenais, GR, Lupien, PJ, Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. Atherosclerosis 119 (1996), 235–245.
4. Wilson, PW, Abbott, RD, Castelli, WP, High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8 (1988), 737–741.
5. McQueen, MJ, Hawken, S, Wang, X, Ounpuu, S, Sniderman, A, Probstfield, J, et al. INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet 372 (2008), 224–233.
6. Pirro, M, Del Giorno, R, Lupattelli, G, Mannarino, MR, Roscini, AR, Covelli, D, et al. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic. Eur J Intern Med 22 (2011), 412–417.
7. Fauconneau, B, Waffo-Teguo, P, Huguet, F, Barrier, L, Decendit, A, Merillon, JM, Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci 61 (1997), 2103–2110.
8. Wang, Z, Huang, Y, Zou, J, Cao, K, Xu, Y, Wu, JM, Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 9 (2002), 77–79.
9. Renaud, S, de Lorgeril, M, Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339 (1992), 1523–1526.
10. Fan, E, Zhang, L, Jiang, S, Bai, Y, Beneficial effects of resveratrol on atherosclerosis. J Med Food 11 (2008), 610–614.
11. Xie, HC, Han, HP, Chen, Z, He, JP, A study on the effect of resveratrol on lipid metabolism in hyperlipidemic mice. Afr J Tradit Complement Altern Med 11 (2013), 209–212.
12. Ren, Y, Li, Y, Zhao, Y, Yu, F, Zhan, Z, Yuan, Y, et al. Effects of resveratrol on lipid metabolism in C57 BL/ 6 J mice. Wei Sheng Yan Jiu 40 (2011), 495–497.
13. Poulsen, MM, Vestergaard, PF, Clasen, BF, Radko, Y, Christenssen, LP, Stodkilde-Jorgensen, H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62 (2013), 1186–1195.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001), 2486–2497.
15. Guerrero-Romero, F, Rodríguez-Morán, M, Pérez-Fuentes, R, Sánchez-Guillén, MC, González-Ortiz, M, Martínez-Abundis, E, et al. Prediabetes and its relationship with obesity in Mexican adults: the Mexican Diabetes Prevention (MexDiab) study. Metab Syndr Relat Disord 6 (2008), 15–23.
16. Chobanian, AV, Bakris, GL, Black, HR, Cushman, WC, Green, LA, Izzo, JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
17. Friedewald, WT, Levy, RI, Fredrickson, DS, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972), 499–502.
18. Bhatt, JK, Thomas, S, Nanjan, MJ, Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32 (2012), 537–541.
19. Timmers, S, Konings, E, Bilet, L, Houtkooper, RH, van de Weijer, T, Goossens, GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14 (2011), 612–622.
20. Zern, TL, Wood, RJ, Greene, C, West, KL, Liu, Y, Aggarwal, D, et al. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 135 (2005), 1911–1917.
21. van der Made, SM, Plat, J, Mensink, RP, Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One, 10, 2015, e0118393.
22. Frémont, L, Belguendouz, L, Delpal, S, Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 64 (1999), 2511–2521.
23. Belguendouz, L, Fremont, L, Linard, A, Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53 (1997), 1347–1355.
24. Brito, P, Almeida, LM, Dinis, TC, The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; protection against LDL oxidation. Free Radic Res 36 (2002), 621–631.
25. Sahebkar, A., Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 71 (2013), 822–835.
26. Iannelli, P, Zarrilli, V, Varricchio, E, Tramontano, D, Mancini, FP, The dietary antioxidant resveratrol affects redox changes of PPARalpha activity. Nutr Metab Cardiovasc Dis 17 (2007), 247–256.
27. Shen, MY, Hsiao, G, Liu, CL, Fong, TH, Lin, KH, Chou, DS, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 139 (2007), 475–485.
28. Csiszar, A, Smith, K, Labinskyy, N, Orosz, Z, Rivera, A, Ungvari, Z, Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 291 (2006), H1694–H1699.
29. Zhang, H, Zhang, J, Ungvari, Z, Zhang, C, Resveratrol improves endothelial function: Role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol 29 (2009), 1164–1171.